Weight Watchers is launching a long-form podcast about GLP-1 drugs, Glossy reports, hosted by former Teen Vogue executive editor Samhita Mukhopadhyay and made with the podcast network Dear Media. The show, called "The Weigh In," launches September 16 and the company says it wants to crush stigma around GLP-1 use.

GLP-1 is the drug class that includes semaglutide (sold as Ozempic and Wegovy) and its competitors, peptide-based medications that mimic a gut hormone involved in appetite and blood sugar regulation. Weight Watchers, 63 years old and rebuilding around those drugs, now sells them through telehealth alongside coaching.

Eight episodes, one big question

The first season runs eight episodes of 45 minutes to an hour, with guests including nutrition expert Dr. Amy Shah, stylist Erin Walsh, The Cut editor-in-chief Lindsay Peoples and SoulCycle founder turned Weight Watchers executive Julie Rice. Mukhopadhyay, who joined the company in March 2025 and has written about her own experience with GLPs for The Cut, told Glossy she plans to take on identity, relationships and culture rather than just how to start.

"There are a lot of assumptions about what it means to take these medications, and there's been a lot of focus on celebrities taking them," she said. Her framing on the drugs themselves is notably unhyped: she hopes to acknowledge that Ozempic and its competitors are not magic bullets, but one piece of a comprehensive medical intervention.

Top of the funnel, and Glossy says so

Glossy is blunt about the commercial logic: the podcast operates as a top-of-funnel marketing endeavor, because Weight Watchers already sells the prescriptions, the telehealth care and the coaching the show will discuss. Mukhopadhyay does not dispute it, telling Glossy that most people do not even know the company sells GLP-1s.

Where the evidence stops

Nothing in this story is a research finding. No trial, outcome figure or published study appears anywhere in it, and the surrounding product line, including AI-powered body composition scans and a wearable-linked "weight health score," is described without any data on what those measures predict.

The open question

A drug seller producing the cultural conversation about its own drug category is not automatically bad journalism, but it is a position with an interest. Whether "The Weigh In" airs the parts of the GLP-1 story that are inconvenient for Weight Watchers is the only test that matters.